AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9699222 — intervention group
Group type: EXPERIMENTAL
Intervention: Capsule A (5 mg MT)
Number of subjects: 15
Study 9699222 — intervention group
Group type: EXPERIMENTAL
Intervention: Capsule B (10 mg MT)
Number of subjects: 15
Study 9699222 — intervention group
Group type: EXPERIMENTAL
Intervention: Capsule C (10 mg MT)
Number of subjects: 15
Study 7989518 — intervention group
Group type: EXPERIMENTAL
Intervention: Assisted hatching with co-culture (AH+CC)
Number of subjects: 100
Study 7989518 — intervention group
Group type: COMPARATOR
Intervention: Assisted hatching alone (AH-alone)
Number of subjects: 100
Study 2524992 — intervention group
Group type: EXPERIMENTAL
Intervention: Baclofen, 60 mg/day
Number of subjects: 60
Study 2524992 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 31733917 — intervention group
Group type: EXPERIMENTAL
Intervention: Super Skills for Life (SSL) intervention group
Number of subjects: 123
Study 31733917 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list control (WLC) group
Number of subjects: 123
Study 29868869 — intervention group
Group type: EXPERIMENTAL
Intervention: TPW located behind the cashier (n = 80)
Number of subjects: 160
Study 29868869 — intervention group
Group type: COMPARATOR
Intervention: TPW hidden behind an opaque wall (n = 80)
Number of subjects: 160
Study 28277874 — intervention group
Group type: EXPERIMENTAL
Intervention: HL301 0.6 g/day
Number of subjects: 160
Study 28277874 — intervention group
Group type: EXPERIMENTAL
Intervention: HL301 1.2 g/day
Number of subjects: 160
Study 28277874 — intervention group
Group type: EXPERIMENTAL
Intervention: HL301 1.8 g/day
Number of subjects: 160
Study 28277874 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 160
Study 28277874 — intervention group
Group type: EXPERIMENTAL
Intervention: All HL301 treatment groups
Number of subjects: 160
Study 25664620 — intervention group
Group type: EXPERIMENTAL
Intervention: Speech recognition intervention
Number of subjects: 1187
Study 25664620 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1187
Study 23466507 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified unilateral laminotomy for bilateral decompression (M‐ULBD)
Number of subjects: 56
Study 23466507 — intervention group
Group type: COMPARATOR
Intervention: Conventional laminectomy
Number of subjects: 56
Study 21680092 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-management training (SMT)
Number of subjects: 171
Study 21680092 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted self-management training (TSMT)
Number of subjects: 171
Study 21680092 — intervention group
Group type: COMPARATOR
Intervention: Continuous oral contraceptive therapy (COCT)
Number of subjects: 171
Study 18455416 — intervention group
Group type: EXPERIMENTAL
Intervention: Radial artery
Number of subjects: 225
Study 18455416 — intervention group
Group type: COMPARATOR
Intervention: Saphenous vein
Number of subjects: 225
Study 16553952 — intervention group
Group type: EXPERIMENTAL
Intervention: W-BQ12 (12-item Well-being Questionnaire)
Number of subjects: 157
Study 16553952 — intervention group
Group type: EXPERIMENTAL
Intervention: GWBI (General Well-being Index)
Number of subjects: 157
Study 16553952 — intervention group
Group type: EXPERIMENTAL
Intervention: W-BQ12
Number of subjects: 157
Study 16553952 — intervention group
Group type: COMPARATOR
Intervention: GWBI
Number of subjects: 157
Study 12596107 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical testosterone application (Testoviron, 2 mg/kg/wk for 3 weeks)
Number of subjects: 26
Study 12596107 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular testosterone injection (same preparation, weekly for 3 weeks)
Number of subjects: 26
Study 10509041 — intervention group
Group type: EXPERIMENTAL
Intervention: Epirubicin/paclitaxel combination plus G‐CSF
Number of subjects: 25
Study 9069029 — intervention group
Group type: EXPERIMENTAL
Intervention: Health risk assessment with targeted follow-up
Number of subjects: 0
Study 9069029 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 2071350 — intervention group
Group type: EXPERIMENTAL
Intervention: 750 mg ciprofloxacin 4 hr before surgery (group I)
Number of subjects: 21
Study 2071350 — intervention group
Group type: EXPERIMENTAL
Intervention: 750 mg ciprofloxacin 8 hr before surgery (group II)
Number of subjects: 21
Study 2071350 — intervention group
Group type: EXPERIMENTAL
Intervention: Two 750 mg doses of oral ciprofloxacin every 12 hr, last dose 12 hr before surgery (group III)
Number of subjects: 21
Study 6343089 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitomycin at 20 mg/20 ml instilled every 2 weeks for the first year and every 4 weeks for the second year starting 3‐4 weeks after TUR
Number of subjects: 58
Study 6343089 — intervention group
Group type: COMPARATOR
Intervention: No further therapy (Control)
Number of subjects: 58
Study 30553932 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised exercise physiotherapy
Number of subjects: 206
Study 30553932 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual physiotherapy
Number of subjects: 206
Study 30553932 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined exercise and manual physiotherapy
Number of subjects: 206
Study 30553932 — intervention group
Group type: COMPARATOR
Intervention: Usual medical care
Number of subjects: 206
Study 30045594 — intervention group
Group type: EXPERIMENTAL
Intervention: Transforaminal (TF) epidural steroid injection
Number of subjects: 40
Study 30045594 — intervention group
Group type: COMPARATOR
Intervention: Interlaminar (IL) epidural steroid injection
Number of subjects: 40
Study 27825987 — intervention group
Group type: EXPERIMENTAL
Intervention: Bacillus subtilis CU1 (2 × 10^9 spores per day for 40 days)
Number of subjects: 0
Study 27825987 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 26561622 — intervention group
Group type: EXPERIMENTAL
Intervention: +AA
Number of subjects: 62
Study 26561622 — intervention group
Group type: COMPARATOR
Intervention: ‐AA
Number of subjects: 62
Study 23138014 — intervention group
Group type: EXPERIMENTAL
Intervention: ivabradine (5 to 7.5mg bid)
Number of subjects: 854
Study 23138014 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 854
Study 21253715 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium plus vitamin D (CaD) supplementation
Number of subjects: 1970
Study 21253715 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1970
Study 18339093 — intervention group
Group type: EXPERIMENTAL
Intervention: Error prevention teaching procedure
Number of subjects: 2
Study 18339093 — intervention group
Group type: COMPARATOR
Intervention: Error correction teaching procedure
Number of subjects: 2
Study 16552809 — intervention group
Group type: EXPERIMENTAL
Intervention: Diuretics plus human albumin 25 g/wk in the first year and 25 g every two weeks thereafter (group 1)
Number of subjects: 100
Study 16552809 — intervention group
Group type: COMPARATOR
Intervention: Diuretics alone (group 2)
Number of subjects: 100
Study 12701663 — intervention group
Group type: EXPERIMENTAL
Intervention: CBT+TAU
Number of subjects: 144
Study 12701663 — intervention group
Group type: COMPARATOR
Intervention: TAU
Number of subjects: 144
Study 11073753 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc gluconate (13.3 mg)
Number of subjects: 554
Study 11073753 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 554
Study 11073753 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc acetate (5 or 11.5 mg)
Number of subjects: 554
Study 11073753 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc gluconate
Number of subjects: 554
Study 11073753 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc acetate
Number of subjects: 554
Study 11073753 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatments (including placebo)
Number of subjects: 554
Study 9322140 — intervention group
Group type: EXPERIMENTAL
Intervention: T10B9.1A-31 (T10B9)
Number of subjects: 9
Study 9322140 — intervention group
Group type: COMPARATOR
Intervention: OKT3
Number of subjects: 9
Study 8250368 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g of cefapirine intravenously every eight hours, four times, starting at induction of anaesthesia
Number of subjects: 72
Study 3957710 — intervention group
Group type: EXPERIMENTAL
Intervention: Retinyl palmitate, 8000 i.u. daily from 30 weeks gestation to term (N=14)
Number of subjects: 44
Study 3957710 — intervention group
Group type: COMPARATOR
Intervention: Control group (N=15)
Number of subjects: 44
Study 3957710 — intervention group
Group type: COMPARATOR
Intervention: Non-Asian controls (N=21)
Number of subjects: 44
Study 3957710 — intervention group
Group type: EXPERIMENTAL
Intervention: Asian women (N=23)
Number of subjects: 44
Study 30316839 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise (walking/jogging on a motor driven treadmill at 70% of age-predicted maximum heart rate, HR = 136.1 ± 11.1 bpm)
Number of subjects: 41
Study 30316839 — intervention group
Group type: COMPARATOR
Intervention: Active control (walking on the treadmill at 0.5 mph and 0% grade, HR = 92.0 ± 12.2 bpm)
Number of subjects: 41
Study 27748551 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine
Number of subjects: 20
Study 27748551 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxycodone
Number of subjects: 20
Study 27748551 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 25035748 — intervention group
Group type: EXPERIMENTAL
Intervention: Deliberate apprenticeship (DA) with senior residents
Number of subjects: 145
Study 25035748 — intervention group
Group type: COMPARATOR
Intervention: Control (unpaired students)
Number of subjects: 145
Study 23075206 — intervention group
Group type: EXPERIMENTAL
Intervention: Permanent stress
Number of subjects: 7251
Study 23075206 — intervention group
Group type: COMPARATOR
Intervention: Periodic stress
Number of subjects: 7251
Study 23075206 — intervention group
Group type: COMPARATOR
Intervention: No stress
Number of subjects: 7251
Study 20087334 — intervention group
Group type: EXPERIMENTAL
Intervention: Helicobacter pylori eradication
Number of subjects: 12
Study 18209674 — intervention group
Group type: EXPERIMENTAL
Intervention: 20% mannitol solution (n = 10 patients)
Number of subjects: 20
Study 18209674 — intervention group
Group type: COMPARATOR
Intervention: 7.45% hypertonic saline solution (HSS) (n = 10 patients)
Number of subjects: 20
Study 16803420 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine 5 or 10 mg/day
Number of subjects: 20
Study 16803420 — intervention group
Group type: COMPARATOR
Intervention: Valsartan 80 or 160 mg/day
Number of subjects: 20
Study 16803420 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine 5 mg, 10 mg, or 10 mg plus hydrochlorothiazide
Number of subjects: 20
Study 16803420 — intervention group
Group type: COMPARATOR
Intervention: Valsartan 80 mg, 160 mg, or 160 mg plus hydrochlorothiazide
Number of subjects: 20
Study 16803420 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine and Valsartan
Number of subjects: 20
Study 14763352 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol (800 micrograms/day)
Number of subjects: 35
Study 14763352 — intervention group
Group type: EXPERIMENTAL
Intervention: Proton Pump Inhibitors (PPI)
Number of subjects: 35
Study 14763352 — intervention group
Group type: EXPERIMENTAL
Intervention: H2-receptor antagonists (H2-RA) at double-dose
Number of subjects: 35
Study 14763352 — intervention group
Group type: COMPARATOR
Intervention: Standard doses of H2-RA
Number of subjects: 35
Study 14763352 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole
Number of subjects: 35
Study 14763352 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol
Number of subjects: 35
Study 10982217 — intervention group
Group type: EXPERIMENTAL
Intervention: Antihistamine alone (n = 13)
Number of subjects: 26
Study 10982217 — intervention group
Group type: EXPERIMENTAL
Intervention: Antihistamine in combination with intranasal corticosteroid (n = 13)
Number of subjects: 26
Study 10982217 — intervention group
Group type: COMPARATOR
Intervention: Baseline
Number of subjects: 26
Study 8815985 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyurethane (Pellethane)
Number of subjects: 12
Study 8815985 — intervention group
Group type: COMPARATOR
Intervention: Silicone (Silastic)
Number of subjects: 12
Study 1406859 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin
Number of subjects: 571
Study 1406859 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 571
Study 2877875 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine (2 mg kg‐1) and alcuronium, supplemented by N2O‐O2 (Group KA)
Number of subjects: 25
Study 2877875 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine (2 mg kg‐1) and alcuronium, supplemented by N2O‐O2 and 0.5% halothane (Group KAH)
Number of subjects: 25
Study 2877875 — intervention group
Group type: COMPARATOR
Intervention: Thiopentone and alcuronium, supplemented by N2O‐O2 and halothane (Control Group TAH)
Number of subjects: 25
Study 29351961 — intervention group
Group type: EXPERIMENTAL
Intervention: REAL Diabetes intervention group (IG)
Number of subjects: 81
Study 29351961 — intervention group
Group type: COMPARATOR
Intervention: Attention control group (CG)
Number of subjects: 81
Study 26955763 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary Care Pathway for Childhood Asthma intervention (electronic guide and train-the-trainer education)
Number of subjects: 0
Study 26955763 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 25216543 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard short infusion (1g imipenem/1g cilastatin over 30min three times daily)
Number of subjects: 22
Study 25216543 — intervention group
Group type: COMPARATOR
Intervention: Extended infusion (0.5g imipenem/0.5g cilastatin over 3h four times daily)
Number of subjects: 22
Study 20686499 — intervention group
Group type: EXPERIMENTAL
Intervention: Olmesartan (10-40 mg) plus amlodipine (5 mg) for 8 weeks
Number of subjects: 755
Study 20686499 — intervention group
Group type: EXPERIMENTAL
Intervention: Olmesartan (up-titrated to 20/5, 40/5 or 40/10 mg) plus amlodipine (5 mg)
Number of subjects: 755
Study 20686499 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine (5 mg) monotherapy
Number of subjects: 755
Study 16162629 — intervention group
Group type: EXPERIMENTAL
Intervention: rescue percutaneous coronary intervention (rPCI) arm
Number of subjects: 307
Study 16162629 — intervention group
Group type: COMPARATOR
Intervention: conservative arm
Number of subjects: 307
Study 11959608 — intervention group
Group type: EXPERIMENTAL
Intervention: Amprenavir (1,200 mg; single dose) with grapefruit juice
Number of subjects: 12
Study 11959608 — intervention group
Group type: COMPARATOR
Intervention: Amprenavir (1,200 mg; single dose) with water
Number of subjects: 12
Study 9647606 — intervention group
Group type: EXPERIMENTAL
Intervention: Zafirlukast
Number of subjects: 0
Study 8029794 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg enoxaparin
Number of subjects: 36
Study 8029794 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg/kg body weight of enoxaparin
Number of subjects: 36
Study 8029794 — intervention group
Group type: COMPARATOR
Intervention: 5000 IU unfractionated heparin (UFH)
Number of subjects: 36
Study 2563743 — intervention group
Group type: EXPERIMENTAL
Intervention: Loratadine, 10 mg once daily
Number of subjects: 228
Study 2563743 — intervention group
Group type: EXPERIMENTAL
Intervention: Terfenadine, 60 mg taken twice daily
Number of subjects: 228
Study 2563743 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 228
Study 1101903 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolfenamic acid (Clotam)
Number of subjects: 31
Study 1101903 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxyphenbutazone
Number of subjects: 31
Study 1101903 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 12423711 — intervention group
Group type: EXPERIMENTAL
Intervention: Glyburide
Number of subjects: 30
Study 12423711 — intervention group
Group type: COMPARATOR
Intervention: Metformin
Number of subjects: 30
Study 31323097 — intervention group
Group type: EXPERIMENTAL
Intervention: Computational observer analysis
Number of subjects: 0
Study 31323097 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased noise in the number of isomerizations of each cone
Number of subjects: 0
Study 31323097 — intervention group
Group type: COMPARATOR
Intervention: Human observers
Number of subjects: 0
Study 30511679 — intervention group
Group type: EXPERIMENTAL
Intervention: Teriflunomide 7 mg
Number of subjects: 148
Study 30511679 — intervention group
Group type: EXPERIMENTAL
Intervention: Teriflunomide 14 mg
Number of subjects: 148
Study 30511679 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 148
Study 27818472 — intervention group
Group type: EXPERIMENTAL
Intervention: NMES with muscle contraction
Number of subjects: 34
Study 27818472 — intervention group
Group type: COMPARATOR
Intervention: NMES without muscle contraction (control group)
Number of subjects: 34
Study 25056227 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone furoate nasal spray (FFNS) 55μg, once daily for two weeks
Number of subjects: 261
Study 25056227 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 261
Study 22774604 — intervention group
Group type: EXPERIMENTAL
Intervention: Anhydrous alcohol sclerotherapy following transrectal ultrasound-guided puncture
Number of subjects: 44
Study 22774604 — intervention group
Group type: COMPARATOR
Intervention: Cystic fluid aspiration only
Number of subjects: 44
Study 20042423 — intervention group
Group type: EXPERIMENTAL
Intervention: Home‐based telemonitored cardiac rehabilitation (HTCR)
Number of subjects: 152
Study 20042423 — intervention group
Group type: COMPARATOR
Intervention: Outpatient‐based standard cardiac rehabilitation (SCR)
Number of subjects: 152
Study 18926076 — intervention group
Group type: EXPERIMENTAL
Intervention: Recruitment Maneuver (RM)
Number of subjects: 40
Study 18926076 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 40
Study 15751094 — intervention group
Group type: EXPERIMENTAL
Intervention: Chondroitin sulfate (CS) 800 mg once daily for 2 years
Number of subjects: 300
Study 15751094 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 300
Study 12005122 — intervention group
Group type: EXPERIMENTAL
Intervention: New portable device (Model H4300 NIKKISO‐YSI CO., LTD.)
Number of subjects: 0
Study 12005122 — intervention group
Group type: COMPARATOR
Intervention: Conventional method (DermaLab, Cortex Technology)
Number of subjects: 0
Study 9769027 — intervention group
Group type: EXPERIMENTAL
Intervention: Propentofylline (PPF) 300 mg t.i.d. for 12 weeks
Number of subjects: 190
Study 9769027 — intervention group
Group type: EXPERIMENTAL
Intervention: Propentofylline (PPF) for 12 weeks
Number of subjects: 190
Study 9769027 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 190
Study 8556421 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training
Number of subjects: 0
Study 2677423 — intervention group
Group type: COMPARATOR
Intervention: Various active treatments for non-small-cell lung cancer
Number of subjects: 150
Study 2677423 — intervention group
Group type: EXPERIMENTAL
Intervention: Various active treatments for small-cell lung cancer
Number of subjects: 150
Study 329743 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg of mianserin
Number of subjects: 20
Study 329743 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg of amitriptyline
Number of subjects: 20
Study 329743 — intervention group
Group type: EXPERIMENTAL
Intervention: mianserin + alcohol (0.5 g/kg)
Number of subjects: 20
Study 329743 — intervention group
Group type: EXPERIMENTAL
Intervention: amitriptyline + alcohol (0.5 g/kg)
Number of subjects: 20
Study 329743 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 30559073 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetuximab monotherapy
Number of subjects: 24
Study 30559073 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetuximab plus capecitabine
Number of subjects: 24
Study 28003574 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined sodium bicarbonate + ascorbic acid
Number of subjects: 429
Study 28003574 — intervention group
Group type: COMPARATOR
Intervention: Saline hydration
Number of subjects: 429
Study 26460474 — intervention group
Group type: EXPERIMENTAL
Intervention: Size Matters handwriting program
Number of subjects: 0
Study 26460474 — intervention group
Group type: COMPARATOR
Intervention: Standard instruction
Number of subjects: 0
Study 22688603 — intervention group
Group type: EXPERIMENTAL
Intervention: Booklet of metaphors and stories conveying key pain biology concepts
Number of subjects: 79
Study 22688603 — intervention group
Group type: COMPARATOR
Intervention: Booklet containing advice on how to manage chronic pain according to established cognitive‐behavioral principles
Number of subjects: 79
Study 21658526 — intervention group
Group type: EXPERIMENTAL
Intervention: DVD-based self-help program
Number of subjects: 24
Study 21658526 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 24
Study 19332424 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive intervention (memory rehabilitation group)
Number of subjects: 52
Study 19332424 — intervention group
Group type: COMPARATOR
Intervention: Waitlist (control group)
Number of subjects: 52
Study 16923322 — intervention group
Group type: EXPERIMENTAL
Intervention: rTMS
Number of subjects: 42
Study 16923322 — intervention group
Group type: COMPARATOR
Intervention: ECT
Number of subjects: 42
Study 15041108 — intervention group
Group type: COMPARATOR
Intervention: Sextant biopsy regimen
Number of subjects: 405
Study 15041108 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-core biopsy strategy
Number of subjects: 405
Study 15041108 — intervention group
Group type: EXPERIMENTAL
Intervention: Re-biopsy including t-zone sampling
Number of subjects: 405
Study 11368985 — intervention group
Group type: EXPERIMENTAL
Intervention: Implanon
Number of subjects: 80
Study 11368985 — intervention group
Group type: COMPARATOR
Intervention: Norplant
Number of subjects: 80
Study 9205765 — intervention group
Group type: EXPERIMENTAL
Intervention: ebrotidine 800 mg
Number of subjects: 50
Study 9205765 — intervention group
Group type: COMPARATOR
Intervention: ranitidine 300 mg
Number of subjects: 50
Study 7708637 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular isoniazid, pyrazinamide+rifampicin
Number of subjects: 265
Study 7708637 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term treatment (12 months and more) with all tuberculostatic agents and surgical intervention
Number of subjects: 265